Market Snapshot: Enterprise Products Partners Misses Estimates, Dollar Gains, Eli Lilly Target Raised

Key Takeaways

  • Enterprise Products Partners LP (EPD) reported Q2 2025 adjusted EBITDA of $2.41 billion, falling short of the estimated $2.43 billion, with distributable cash flow (DCF) also missing expectations at $1.94 billion against an estimated $1.95 billion.
  • The U.S. Dollar Index (DXY) surged by 0.57% to 98.21, indicating a strengthening dollar against a basket of major currencies.
  • BMO Capital has raised its target price for Eli Lilly (LLY) to $920 from $900, maintaining an "Outperform" rating on the pharmaceutical giant.

Midstream energy giant Enterprise Products Partners LP (EPD) announced its second-quarter 2025 earnings, with key financial metrics slightly under analyst expectations. The company posted adjusted EBITDA of $2.41 billion, narrowly missing the estimated $2.43 billion. Similarly, distributable cash flow (DCF) came in at $1.94 billion, just below the $1.95 billion consensus estimate. Earnings per unit (EPU) were reported at $0.66.

In currency markets, the U.S. Dollar Index (DXY) experienced a notable rise, climbing 0.57% to reach 98.21. This upward movement suggests a strengthening of the dollar against other major global currencies, a trend that could impact international trade and corporate earnings for multinational companies. The dollar index has seen significant volatility recently, including an 11% slump in the first half of 2025, its worst first-half performance since 1973, driven by factors such as Trump's tariff policies and the Federal Reserve's dovish outlook.

Meanwhile, pharmaceutical powerhouse Eli Lilly (LLY) received a positive adjustment to its target price from BMO Capital. The investment firm increased its price target to $920 from $900, while reiterating an "Outperform" rating. This revised target comes amid ongoing developments for Eli Lilly, including anticipation around its presymptomatic Alzheimer's trial, TRAILBLAZER-ALZ 3, which could see an interim analysis earlier than market expectations. A positive readout from this trial could significantly boost sentiment around beta-amyloid Alzheimer's therapies and potentially expand the long-term market for patients without progressed disease.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. We are not financial professionals. The authors and/or site operators may hold positions in the companies or assets mentioned. Always do your own research before making financial decisions.
Scroll to Top